ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,381Medicare Part D Prescriptions Filled, Including Refills

Rank: 491 out of 3001

$590K Total Retail Price of All Prescriptions

Rank: 456 out of 3001

469 Patients Receiving at Least One Drug in Part D
42%Patients 65 Years and Older
73% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Ohio
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 469 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

6% of this provider’s 469 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

3% of this provider’s 3,991 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$63 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Ohio
LEVOTHYROXINE SODIUM 437 183 1 3
LISINOPRIL 380 203 2 2
PRAVASTATIN SODIUM 346 178 3 13
OMEPRAZOLE 275 106 4 4
METFORMIN HCL 256 95 5 9
SIMVASTATIN 237 120 6 1
AMLODIPINE BESYLATE 212 128 7 5
ATENOLOL 196 78 8 18
HYDROCHLOROTHIAZIDE 184 90 9 10
PROAIR HFA 175 57 10 30
NEXIUM 168 74 11 23
ATORVASTATIN CALCIUM 160 20 12 11
FUROSEMIDE 156 81 13 6
GABAPENTIN 155 52 14 14
LOVASTATIN 144 91 15 38
SPIRIVA 135 47 16 57
RANITIDINE HCL 123 48 17 41
LOSARTAN POTASSIUM 112 71 18 21
CITALOPRAM HBR 112 62 18 16
METFORMIN HCL ER 101 62 20 51
METOPROLOL TARTRATE 92 65 21 8
CYMBALTA 91 24 22 53
CRESTOR 91 68 22 33
SERTRALINE HCL 85 50 24 20
ALENDRONATE SODIUM 83 68 25 26
FLUTICASONE PROPIONATE 80 27 26 42
FENOFIBRATE 79 39 27 59
TRAZODONE HCL 79 41 27 37
SYMBICORT 79 27 27 155
TRAMADOL HCL 79 29 27 17
HYDROCODONE-ACETAMINOPHEN 78 63 S3 31 7
CYCLOBENZAPRINE HCL 77 0 R 32 73
FLUOXETINE HCL 75 18 33 61
GLIMEPIRIDE 75 16 33 31
POTASSIUM CHLORIDE 72 23 35 15
ZOLPIDEM TARTRATE 71 0 36 24
IBUPROFEN 71 0 36 74
CLOPIDOGREL 69 43 38 28
QUETIAPINE FUMARATE 66 0 39 66
AMITRIPTYLINE HCL 65 35 R 40 85
GLYBURIDE 64 37 R 41 62
ALLOPURINOL 64 41 41 35
VENLAFAXINE HCL ER 61 12 43 103
TAMSULOSIN HCL 58 20 44 29
PEN NEEDLE 51 0 45 128
TRICOR 50 18 46 132
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 11, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.